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BACKGROUND AND PURPOSE
Thrombin is massively released upon tissue damage associated with bleeding or chronic inﬂammation. The effects of this
thrombin on tissue regrowth and repair has been scarcely addressed and only in cancer cell lines. Hence, the purpose of the
present study was to determine thrombin’s pharmacological effects on human intestinal epithelium growth, proliferation and
apoptosis, using three-dimensional cultures of human colon organoids.
EXPERIMENTAL APPROACH
Crypts were isolated from human colonic resections and cultured for 6 days, forming human colon organoids. Cultured organoids
were exposed to 10 and 50 mU·mL1 of thrombin, in the presence or not of protease-activated receptor (PAR) antagonists.
Organoid morphology, metabolism, proliferation and apoptosis were followed.
KEY RESULTS
Thrombin favoured organoid maturation leading to a decreased number of immature cystic structures and a concomitant
increased number of larger structures releasing cell debris and apoptotic cells. The size of budding structures, metabolic activity
and proliferation were signiﬁcantly reduced in organoid cultures exposed to thrombin, while apoptosis was dramatically
increased. Both PAR1 and PAR4 antagonists inhibited apoptosis regardless of thrombin doses. Thrombin-induced inhibition of
proliferation and metabolic activity were reversed by PAR4 antagonist for thrombin’s lowest dose and by PAR1 antagonist for
thrombin’s highest dose.
CONCLUSIONS AND IMPLICATIONS
Overall, our data suggest that the presence of thrombin in the vicinity of human colon epithelial cells favours their maturation at
the expense of their regenerative capacities. Our data point to thrombin and its two receptors PAR1 and PAR4 as potential
molecular targets for epithelial repair therapies.
Abbreviations
IBD, inﬂammatory bowel disease; NAC, N-acetylcysteine; PAR, protease-activated receptor; PFA, paraformaldehyde; RT,
room temperature
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Introduction
A new paradigm has been set up for the treatment of
inﬂammatory bowel diseases (IBDs), shifting from re-
solving symptoms and inﬂammation per se (i.e. inﬁltra-
tion and activation of inﬂammatory cells), towards the
objective of tissue repair and mucosal healing (Iacucci
and Ghosh, 2016). Indeed, mucosal healing and epithe-
lial repair are increasingly incorporated in the outcome
measures of clinical trials (Shah et al., 2016). This new
focus on epithelial regeneration and healing has shed
new light on intestinal epithelial cell biology and
drives a new area of research for the development of
therapeutic approaches for IBD. The study of mediators
that are released in the course of chronic intestinal in-
ﬂammation and their effects on epithelial biology
has become a major focus of research for drug
development.
In that setting, thrombin appears as a most impor-
tant candidate, since IBD patients exhibit abnormalities
in coagulation and ﬁbrinolysis, have an increased throm-
bin generation and a signiﬁcant presence of this protease
in colonic tissues (de Jong et al., 1989; Senchenkova
et al., 2015). Therefore, the effects of thrombin on human
epithelial tissues have to be carefully considered. Previous
studies have investigated the effects of thrombin on intes-
tinal cancer cell lines (Darmoul et al., 2003), demonstrating
that thrombin provoked dramatic mitogenic responses,
proliferation and increased cell migration. These studies
suggested that thrombin could be a growth factor for hu-
man colon cancer. However, the effects of thrombin on in-
testinal epithelium have only been studied in cancer cells,
which are known to overexpress thrombin receptors
(Darmoul et al., 2003; Gratio et al., 2009). What are the ef-
fects of thrombin chronic exposure on non-transformed
and non-cancerous human intestinal epithelial cells? Does
thrombin modify epithelial proliferation, apoptosis of
non-cancerous cells or regeneration in intestinal tissues?
Does the presence of thrombin modify epithelial repair in
the context of IBD?
The recent development of human colon organoid
cultures allows pharmacological testing of compounds
in three-dimensional (3D) primary cell cultures in com-
plex human epithelia (Sato et al., 2011; Crespo et al.,
2017). Indeed, organoid cultures are representative of
the complex composition of intestinal epithelium, since
within the same organoid, after a few days of culture,
stem cells, progenitors and differentiated cells are de-
tected (Sato et al., 2011). In the present study, we took
advantage of this model to test the effects of thrombin
on human healthy epithelium. This model replicates the
cell composition of a physiological epithelium, and,
therefore, pharmacological approaches using a more
physiological model are also more relevant to predict a
drug’s effects. Since renewal of damaged epithelium and
epithelial repair implicate cell survival, growth and pro-
liferation, our aim was to determine the effects thrombin
has on these parameters in human colon organoid cul-
tures and to study the potential involvement of the two
active thrombin receptors: protease-activated receptor
(PAR)1 and PAR4.
Methods
Human samples
Biological samples were obtained from ﬁve different
patients treated at the Toulouse University Hospital. Patients
gave informed consent and were included in the registered
COLIC study (DC-2015-2443). Colonic samples were ob-
tained from surgical resections of patients suffering from
colorectal cancer. Tissues that were used were harvested in
healthy zones at the margin of the resection and at least
10 cm away from the tumour. Characteristics and treatments
of patients are provided in Supporting Information Table S1.
Organoid cultures
Tissue obtained was opened longitudinally and washed
with Dulbecco’s PBS (DPBS; Sigma-Aldrich #D8537, Saint-
Quentin-Fallavier, France). Then, the mucosa was removed
and incubated in an antibiotic solution (gentamicin
Sigma-Aldrich #G1397, Saint-Quentin-Fallavier, France,
1000×; normocin InvivoGen #ANT-NR-1, Toulouse, France,
500×; and fungizone Gibco #15290-018, Illkirch, France,
100×) for 5 min at room temperature (RT), four times. The
mucosa was cut into 0.2- to 0.5-cm-long pieces and placed
in a Petri dish containing cold DPBS before a series of three
incubations in a 10 mMDTT (Roche #10197777001, Meylan,
France) solution, for 5 min at RT. Pieces of tissue were trans-
ferred into a 8 mM EDTA (Ambion #L/N.1408029, Dardilly,
France) solution and were left under gentle rocking for 1 h
at 4°C. Supernatants were removed and replaced by 10 mL
of DPBS. Mucosa fragments were then resuspended by vigor-
ous manual up and down shaking (at least 15 repeated move-
ments). Supernatants were recovered into a new 15mL falcon
tube and centrifuged for 2min, 40× g at 4°C. Ten millilitres of
DMEM/F12 (Invitrogen #12634-010, Illkirch, France) supple-
mented with 100× Glutamax-CTS (Invitrogen #A1286001,
Illkirch, France), 100× HEPES (Gibco #15630-056, Illkirch,
France) and 5% FBS was added to the pellets and centrifuged
again for 2min, 40× g at 4°C. This step was repeated twice.
Then, crypts were counted in a 20 μL drop and the samples
were centrifuged once again for 2min, at 40× g at 4°C. Super-
natants were removed, and fresh hES Matrigel (Corning
#354277, Amsterdam, Netherlands) was added to the pellets,
carefully avoiding air bubbles. Tenmicrolitres of Matrigel
containing 20 crypts were plated in eachwell of a pre-warmed
96-well plate (Ibidi, Martinsried, Germany μ-angiogenesis).
Once the Matrigel had polymerized for 20 min, 70 μL of cul-
ture medium was added to each well. The culture medium
was composed of 50% advanced DMEM/F12, 50% Wnt3a-
conditioned medium [supernatants from L Wnt-3A cells
(ATCC® CRL-2647™)], 100× Glutamax-CTS, 100× HEPES,
serum-free B27 (Life Technologies #12587-010, Villebon-
sur-Yvette, France, 50×), N2 (Invitrogen #17502-048, Illkirch,
France 100×), N-acetylcysteine (NAC; Sigma #A9165-5G,
Saint-Quentin-Fallavier, France 500×), nicotinamide (Sigma
#N0636, Saint-Quentin-Fallavier, France 10 mM), recombi-
nant human epithelial growth factor (Gibco #PHG0314,
Illkirch, France 50 ng·mL1), human Noggin (Tebu #120-
10C, Le-Perray-en-Yvelines, France 100 ng·mL1), human R-
spondin (R&D #4645RS, Lille, France 1 μg·mL1), gastrin
(Sigma G9145, Saint-Quentin-Fallavier, France 10 nM),
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SB202190 (Sigma 57067, Saint-Quentin-Fallavier, France
10 μM), LY2157299 (Axon MedChem #1941, Groningen,
Netherlands 0.5 μM) and PGE2 (Sigma #P0409, Saint-
Quentin-Fallavier, France 0.01 μM). The cultures were ﬁnally
incubated in a humidiﬁed incubator at 37°C and 5% CO2.
The culture medium was changed every 3 days but without
NAC and LY2157599.
Treatments with thrombin and antagonists
Thrombin (Sigma-Aldrich #T6884, Saint-Quentin-Fallavier,
France) diluted in 0.1% BSA (Sigma-Aldrich #A9576, Saint-
Quentin-Fallavier, France) was added to culture media daily
starting from day 3 and until day 6, at two different doses:
10 and 50 mU·mL1. Forty-ﬁve minutes before each addition
of thrombin to culture media, the PAR1 antagonist F16357
(Pierre Fabre Medicaments, Toulouse, France), PAR4 antago-
nist ML354 (Tocris #5387, Lille, France) or their vehicle
(0.02% DMSO) was added to the media, according to the pro-
tocol described in Supporting Information Figure S1. The
doses of thrombin used were selected according to previously
published studies investigating the effects of thrombin in cell
culture systems (Harmon et al., 1986; Morganti et al., 2010).
Similarly, at the doses selected, the PAR1 (10 μM), and PAR4
(140 nM) antagonists were proven to speciﬁcally inhibit
these receptors in cell culture models (Planty et al., 2010;
Young et al., 2010; Wen et al., 2014; Monjotin et al., 2016).
All cultures were stopped at day 6 for analysis.
Images of cultures and analysis
Structures were imagedusing an apotomemicroscope (HXP120;
Zeiss Axio-observer, Marly-le-roi France; 10×, 0.45 NA) from the
Toulouse-Purpan Imaging Core facility directed by Sophie
Allart. Imageswere analysed using the ImageJ software fromFiJi.
For immunostaining, organoids were analysed with an inverted
confocal microscope, Spinning Disk (Flash4 CSU 1×, 234 z
0.5 μm, with stream, 20× 0.75 NA, 234 z-planes and 1.5 μm
spacing). 3D reconstruction and analysis for each organoid
acquired were done with Imaris software (8.2; Bitplane).
Classification of cultures
Structures were classiﬁed according to the presence of rounded
or immature cells and budding between the harvesting and the
6 days of culture, as described by the intestinal stem cell
consortium (Stelzneret al., 2012) (a nomenclature for intestinal
in vitro cultures). With regard to columnar structures, the cell
polarity was deﬁned by the polarized labelling of β-actin and
β-catenin. A columnar cell was deﬁned by a thickness
>18 μm. Releasing structures were deﬁned by a broken epithe-
lium and the presence of cell debris inside and outside of the
structure. For all structures, the diameters around the structure
were measured four times, and measurements obtained were
averaged. For budding structures, only the rounded core of
the structure was measured for diameter; individual budding
zones were not included in the diameter measurements.
Metabolic activity assay
TheCellTiter-Glo® 3D reagent (Promega, #9683, Charbonniere-
Les-Bains, France) kit was used tomeasure extracellularATP, as
an indication of mitochondrial metabolic activity within the
cultures (Zanoni et al., 2016). The reagent was added to the cul-
ture medium of each well (volume 1:1) and incubated for
30 min at RT, protected from light, as per the manufacturer’s
instructions. Luminescence was measured with a luminometer
(Varioskan Flash – Thermo Scientiﬁc, Illkirch, France). A mini-
mum of three wells per condition was analysed and measured
and was calculated using an ATP standard curve. Because image
acquisition of cells was not possible in the whole well, the ATP
concentrations were normalized to the total surface area
occupied by the cultured cell structures, as observed by micro-
scopic analysis using bright ﬁeld imaging using an apotome
microscope. Therefore, the cell surface area was used to control
for amount of tissue variation.
Apoptosis assay
Apoptosis was quantiﬁed using the NucView 488 caspase-3
kit (Ozyme, 1 mM in 1× PBS #BTM10403, Saint-Quentin-
Fallavier, France), at day 6, where active caspase-3 is detected
as a measure of apoptotic cells. As per the manufacturer’s
instructions, the NucView 488 reagent was added to culture
medium of each well (volume 1:1) and incubated for 30 min
at RT, and protected from light. Nuclei were stained using
DAPI, as previously described (Gobbetti et al., 2015). The ﬂuo-
rescence emitted was measured with a confocal microscope
(Spinning Disk – CSU-X1 – Flash4 camera – 20×, 0.75 NA).
Ten organoids were analysed per condition with 234 z-planes
and 1.5 μm spacing, except for the second patient (thrombin
10 mU·mL1 and F16357 10 μM, only two organoids were
analysed) and the third patient (for the thrombin 50mU·mL1
condition, no organoid was analysed). The 3D reconstruction
and analysis of number of caspase-3-positive cells (stained by
DAPI as previously described; Cenac et al., 2010) in the total
number of cells in each organoid were done with Imaris soft-
ware 8.2, Bitplane. Only caspase-3-positive cells present within
the lining of the organoid epithelium were counted; positive
cells present in the lumen were not considered.
Proliferation measurements
Organoids were ﬁxed with 3.7% paraformaldehyde (PFA;
Sigma-Aldrich, Saint-Quentin-Fallavier, France) in PBS at 37°C
for 20 min. Organoids were permeabilized with 0.5% triton
X-100 (Sigma-Aldrich, Saint-Quentin-Fallavier, France) in PBS
at RT for 20 min and were incubated with a blocking buffer
with 3% BSA (Sigma-Aldrich, Saint-Quentin-Fallavier, France)
in PBS 1.5 h at 37°C. Organoids were then incubated for 2 h
at 37°C with primary antibody anti-Ki67, mouse Ig G1 (Dako,
#M7240, Les-Ulis, France 1/100). Next, the primary antibody
was washed out three times for 5 min, and organoids were in-
cubated with the secondary antibody, AlexaFluor 568 donkey
anti-mouse (Life Technologies, #A10038, Villebon-Sur-Yvette,
France 1/500) for 1.5 h at 37°C and then stained for 20 min
with DAPI (Invitrogen, Illkirch, France). Plates were mounted
with Vectashield mounting medium (Eurobio, Les-Ulis,
France), and organoids were analysed with an inverted confo-
cal microscope, Spinning Disk (Flash4 sCMOS, 234 z 0.5 μm,
with stream, 20× 0.75 NA). All organoids were analysed for
each condition with 234 z-planes and 1.5 μm spacing, more
precisely as follows:
• First patient: control: 8 organoids analysed; thrombin
10 mU·mL1: 7 organoids; thrombin 50 mU·mL1: 6
organoids; thrombin 10mU·mL1 andML354: 10 organoids;
thrombin 50 mU·mL1 and ML354: 10 organoids; thrombin
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10 mU·mL1 and F16357: 10 organoids; thrombin 50-
mU·mL1 and F16357: 10 organoids; ML354 140 nM: 7
organoids; and F16357 10 μM: 10 organoids.
• Second patient: control: 10 organoids analysed; thrombin
50 mU·mL1: 8 organoids; thrombin 10 mU·mL1 and
ML354: 9 organoids; thrombin 50 mU·mL1 and ML354: 5
organoids; thrombin 10 mU·mL1 and F16357: 9 organoids;
thrombin 50 mU·mL1 and F16357: 8 organoids; ML354
140 nM: 10 organoids; and F16357 10 μM: 5 organoids.
• Third patient: control: 10 organoids analysed; thrombin
10 mU·mL1: 8 organoids; thrombin 50 mU·mL1: 6
organoids; thrombin 10mU·mL1 andML354: 5 organoids;
thrombin 50 mU·mL1 and ML354: 6 organoids; and
thrombin 50 mU·mL1 and F16357: 5 organoids.
• Fourth patient: control: 7 organoids analysed; thrombin 10-
mU·mL1: 10 organoids; thrombin 10 mU·mL1 and
ML354: 5 organoids; thrombin 50 mU·mL1 and ML354: 6
organoids; thrombin 10mU·mL1 and F16357: 10 organoids;
thrombin 50 mU·mL1 and F16357: 6 organoids; ML354
140 nM: 10 organoids; and F16357 10 μM: 8 organoids.
• Fifth patient: control: 10 organoids analysed; thrombin
10 mU·mL1: 10 organoids; thrombin 50 mU·mL1: 7
organoids; thrombin 10mU·mL1 andML354: 7 organoids;
thrombin 50 mU·mL1 and ML354: 6 organoids; thrombin
10 mU·mL1 and F16357: 5 organoids; thrombin
50 mU·mL1 and F16357: 6 organoids; ML354 140 nM: 7
organoids; and F16357 10 μM: 5 organoids.
3D reconstruction and analysis of Ki67-positive cells per
total cells (stained by DAPI) in individual organoids were per-
formed with Imaris software 8.2, Bitplane.
Real-time PCR
Total RNA was extracted from organoid cultures using TRIzol
Plus RNA Puriﬁcation Kit (Invitrogen, Illkirch, France) as pre-
viously described (D’Aldebert et al., 2011). Real-time PCR was
performed with PAR1 and PAR4 gene-speciﬁc primers:
50AAGAAAGTTCCGATCCCAGC30 and 50TTTTAACCTCC
CAGCAGTCC30 for PAR1; 50TGCGTGGATCCCTTCATCT
AC30 and 50CCTGCCCGCACCTTGTC30 for PAR4. The rela-
tive expression of targeted genes was compared with that of
hypoxanthine phosphoribosyltransferase.
PAR1 immunohistochemistry
As for Ki67 immunostaining, organoids were ﬁxed with 3.7%
PFA (Sigma-Aldrich, Saint-Quentin-Fallavier, France) in PBS
at 37°C for 20 min, permeabilized with 0.5% triton X-100
(Sigma-Aldrich, Saint-Quentin-Fallavier, France) in PBS at RT
for 20 min and were incubated with a blocking buffer at 3%
BSA (Sigma-Aldrich, Saint-Quentin-Fallavier, France) in PBS
for 1.5 h at 37°C. Organoids were then incubated overnight
with anti-PAR1 primary antibody (AB111976; Abcam,
Cambridge, UK) at a concentration of 1:500 as previously de-
scribed (Desormeaux et al., 2018). After being washed,
organoids were incubated with secondary antibody (Alexa
Fluor) for 1 h, washed and mounted with Prolong Gold
Reagent containing DAPI (Molecular Probes, Leiden,
Netherlands), for nucleus staining. Controls for the speciﬁc-
ity of the antibody include incubation in the absence of
secondary antibody and in the presence of immunizing pep-
tides (not shown).
Randomization, blinding and statistical
analysis
All organoids present in wells were counted. For all experi-
ments, plates were prepared so that all conditions were ran-
domly present in each plate. Organoid counts and measures
were performed by an observer unaware of the treatments.
Data are expressed as mean ± SEM. Analyses were per-
formed using the GraphPad Prism 6.0 software. Statistical sig-
niﬁcance was determined by one-way ANOVA followed by
Bonferroni multiple comparisons test. Signiﬁcance was ac-
cepted for P < 0.05. Post hoc tests were run only if F achieved
P < 0.05 and when no signiﬁcant variance inhomogeneity
was observed. The data and statistical analysis comply with
the recommendations on experimental design and analysis
in pharmacology (Curtis et al., 2018).
Nomenclature of targets and ligands
Key protein targets and ligands in this article are hyperlinked to
corresponding entries in http://www.guidetopharmacology.
org, the common portal for data from the IUPHAR/BPS Guide
to PHARMACOLOGY (Harding et al., 2018), and are
permanently archived in the Concise Guide to PHARMACOL-
OGY 2017/18 (Alexander et al., 2017a,b).
Results
Characterization of organoid cultures
Human colon crypts were puriﬁed from fresh tissue samples
obtained from colectomies harvested in healthy zones of
tissues from patients diagnosed with colorectal cancer
(Supporting Information Table S1). Isolated crypt fragments
(Figure 1A, day 0 panel) were cultured in 3D Matrigel matrix
for 3 and 6 days. Within the ﬁrst day, the crypt architecture dis-
appeared (not shown) to form organoid structures composed of
an epithelial cell monolayer and a central lumen. At day 3 of
culture, three types of structures were observed: ‘cystic’, ‘co-
lumnar’ and ‘releasing’ structures (Figure 1A, day 3 panel). Cys-
tic structures were characterized by ﬂat epithelial cells
organized to delineate a clear lumen (Figure 1A). Epithelial cells
comprising cystic organoids are typically immature and undif-
ferentiated with high proliferative and self-renewal capacities
(Ramalingam et al., 2012; Stelzner et al., 2012). Columnar struc-
tures were characterized by thicker epithelial cells, still
monolayered, but with a columnar shape for all epithelial cells,
similar to the shape of cells found in the native crypts (Figure-
1A). Nuclei in columnar cells were stained on the basal portion
of the cells. Epithelial cells from columnar structures typically
undergo both proliferation and limited differentiation
(Ramalingam et al., 2012). The lumen of these structures could
appear clear, or contain cellular debris. Releasing structures
were characterized by their large size, the columnarity of the
cells composing their shape and the presence of a crater that
seems to allow the release of intraluminal debris (Figure 1A).
At day 6 of culture, the same three types of structure were
observed (Figure 1A, day 6 panel), and in addition, ‘budding’
structures were present. Budding structures are characterized
by excrescences of new crypts and exemplify fully mature and
differentiated organoids with both proliferative and differentia-
tion capacities. These types of structures are called colonoids
and were rare in our culture conditions (6 days of culture).
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The size of each type of structure was measured at day 6 of
culture (Figure 1B) and showed a trend of increasing size from
the most immature structures (cystic) to the most mature
structures (releasing and budding).
Effects of thrombin exposure on human colon
organoid cultures
Thrombin was added to the human organoid cultures daily
from day 3 to day 6 of the culture (Supporting Information
Figure S1). For the two doses of thrombin used (10 and
50 mU·mL1), no difference in the total number of organoids
was observed (not shown). Similarly, the size of cystic, colum-
nar or releasing organoids was not changed by the addition of
thrombin (Figure 2A). However, at the dose of 10 mU·mL1,
the addition of thrombin to human colon organoid cultures
caused a signiﬁcant decrease in the size of budding organoids,
while the higher dose of 50mU·mL1 had no effect (Figure 2A).
While chronic incubation of human colon organoid cul-
tures with thrombin had no effect on the percentage of colum-
nar organoids present in the culture, thrombin (both 10 and
50 mU·mL1) signiﬁcantly affected the number of cystic
organoids and increased the proportion of releasing organoids
(Figure 2B). No signiﬁcant effect was observed on the propor-
tion of budding organoids in the presence of thrombin, but a
trend towards an increased number of budding structures in
the presence of thrombin could be noticed (Figure 2B). Taken
together, these data suggest that thrombin exposure pushes
colon organoid cultures towards maturation.
The concentration of ATP release per surface of total
organoids was used as a measure of metabolic activity/cell
survival in organoid cultures. Thrombin incubation (both
at 10 and 50 mU·mL1) signiﬁcantly reduced the metabolic
activity of human colon organoid cultures (Figure 3).
Apoptosis was signiﬁcantly increased in epithelial cells lining
within organoids exposed to both doses of thrombin
(Figure 4). Immunostaining for apoptotic cells was particu-
larly strong in the lumen of the structures (microphotographs
on the panel) both in control conditions and after
thrombin exposure. Such staining corresponds to physiolog-
ical anoikis. However, in the case of thrombin exposure,
apoptotic cells were also present within the cell lining of
organoid structures (right panel photomicrograph). The
percentage of proliferative cells (Ki67-positive cells) was
signiﬁcantly diminished in the presence of thrombin (both
doses) (Figure 5).
Thrombin-induced effects on human colon
organoid cultures are mediated by the activation
of both PAR1 and PAR4
First, we investigated the presence of PAR1 and PAR4 in the
material used. Both PAR1 and PAR4 mRNAs were detected
in crypts isolated from human intestinal tissues (not shown).
RT-PCR experiments showed that PAR1 and PAR4 mRNAs
were present in 6 day organoid cultures, and this expression
was signiﬁcantly increased by exposure of cultures to increas-
ing doses of thrombin (Figure 6A). Immunohistochemistry
performed on organoids after 6 days of culture revealed that
PAR1 was expressed on almost all epithelial cells (Figure 6B).
Compared with the localization of the nucleus stained by
DAPI, PAR1 expression appeared mostly on the basolateral
side (Figure 6B). The addition of PAR1 or PAR4 antagonists
alone to the cultures had no effect on the size of organoid sub-
types (Supporting Information Figure S2), or on the types
(cystic, columnar, releasing or budding) of organoids present
Figure 1
Organoid characterization. (A) Microphotographs of isolated crypts at day 0 of culture, representative cystic, columnar and releasing organoids at
days 3 and 6 of culture and representative budding structure at day 6 of organoid culture. Scale bar is 100 μm. (B) Organoid diameter (μm), at day
6 of culture. Data are means ± SEM, organoids n = 39 for cystic, n = 85 for columnar, n = 23 for releasing and n = 3 for budding. These data are
representative of organoid cultures originating from ﬁve individuals.
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in the culture (Supporting Information Figure S2). Thrombin-
induced decrease in per cent of cystic structures was reversed
similarly by PAR1 and PAR4 antagonist treatment, indepen-
dently of the dose of thrombin used (Figure 7A for the dose
of 50 mU·mL1, not shown for the 10 mU·mL1 thrombin
dose). Thrombin-induced increase in per cent of releasing
structures was signiﬁcantly reversed by PAR1 but not by
PAR4 antagonist treatment, independently of the dose of
thrombin used (Figure 7B for the dose of 50 mU·mL1, not
shown for the 10 mU·mL1 dose). PAR4 antagonist treatment
signiﬁcantly decreased the per cent of budding structures ob-
served in the presence of thrombin at the dose of 50mU·mL1
(Figure 7C). Thrombin had no effect on the per cent of colum-
nar structures (Figure 2B), and treatments with PAR1 or PAR4
antagonist did not change this observation (data not shown).
PAR1 or PAR4 antagonists had no effect on the size of
organoids exposed to thrombin, regardless of the dose of
thrombin used (Supporting Information Figure S3). The de-
creased metabolic activity induced by the lowest dose of
thrombin was inhibited by a pre-incubation with the PAR4
antagonist ML354 but not by the PAR1 antagonist F16357.
In contrast, the effect of the highest dose of thrombin
(50 mU·mL1) was only inhibited by the PAR1 antagonist
and not by the PAR4 antagonist (Figure 7D). The effects of
all doses of thrombin on apoptosis were completely
abolished by both the PAR1 and the PAR4 antagonists, indi-
cating that both receptors play a role in thrombin-induced
apoptosis, regardless of the dose (Figure 7E). Thrombin-
induced decrease in percentage of proliferative cells was
inhibited by the PAR4 antagonist for the low dose of throm-
bin (10mU·mL1) but not by the PAR1 antagonist (Figure 7F).
The effects of the highest dose of thrombin (50 mU·mL1) on
Figure 2
Effects of thrombin (THRB) on organoid characteristics. (A) Diameter (μm) of cystic, columnar, releasing and budding organoids at 6 days of cul-
ture and after 3 days of exposure to thrombin at 10 or 50 mU·mL1 or to vehicle. (B) The percentage of the different types of structures, at 6 days
of culture and after 3 days of exposure to thrombin at 10 or 50 mU·mL1 or to vehicle. Data are means ± SEM with n = 5 different individuals from
which tissues were harvested, and 70 organoids were analysed per condition. *P< 0.05 (one-way ANOVA, Bonferroni multiple comparisons test).
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the percentage of proliferative cells in organoid cultures were
inhibited by the PAR1 but not by the PAR4 antagonist
(Figure 7F).
Discussion
The present study investigated the effects of thrombin on the
biology of the human intestinal epithelium, with the aim of
determining whether exogenous thrombin could eventually
modify epithelial growth and/or renewal. We demonstrated
that exogenous thrombin favoured organoid maturation, also
induced severe apoptosis, and reduced the metabolic activity
and proliferation of human intestinal epithelial cells. Overall,
our data suggest that the presence of thrombin in the vicinity
of epithelial cells is detrimental to epithelial renewal. Further-
more, we demonstrated that these detrimental effects of
thrombin are mediated by the activation of both PAR1 and
PAR4, the two functional thrombin receptors. We have previ-
ously demonstrated that PAR1 is expressed in human and
mouse colon crypts and organoids (Nasri et al., 2016). The
presence of PAR4 in stem cells/progenitors has not been previ-
ously demonstrated, but our results revealed an active role for
PAR4 in these cells. These ﬁndings are particularly relevant in
the context of IBD, where large amounts of thrombin are pres-
ent in a patient’s intestinal tissues (de Jong et al., 1989). Poten-
tially, thrombin could be present both on the basolateral side of
epithelial cells as per blood vessel rupture and in the lumen
upon bloody diarrhoea associated with IBD. Our data point to
a basolateral effect of thrombin and its two receptors PAR1
and PAR4, as potential molecular targets for epithelial repair
therapies. Indeed, previous studies have demonstrated a role
Figure 3
Effects of thrombin (THRB) on organoid metabolic activity. Concen-
tration of ATP released per total surface of organoids as a measure of
metabolic activity/cell survival in 6 day organoid cultures exposed to
thrombin (10 or 50 mU·mL1) or to vehicle. Data are means ± SEM
with n = 5 different individuals fromwhich tissues were harvested. In-
dividual sign shape represents data generated from the culture of the
same patient tissue. *P< 0.05 (one-way ANOVA, Bonferroni multiple
comparisons test).
Figure 4
Effects of thrombin (THRB) on organoid cell apoptosis. The % of apoptotic cells (red staining) present in epithelial lining of organoid structures
over total cells (cyan DAPI nucleus staining) per organoid cultured for 6 days and exposed for the last 3 days of culture to thrombin (10 or
50mU·mL1) or vehicle. Data are means ± SEMwith n = 5 different individuals fromwhich tissues were harvested. Individual sign shape represents
data generated from the culture of the same patient tissue. *P< 0.05 (one-way ANOVA, Bonferroni multiple comparisons test). Photomicrographs
are representative pictures of caspase-3 staining in control condition (vehicle exposure) (left panel), thrombin 10 mU·mL1 incubation (middle
panel) or thrombin 50 mU·mL1 (right panel) incubation. Scale bar is 50 μm.
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Figure 5
Effects of thrombin (THRB) on organoid cell proliferation. The % of proliferative cells (Ki67 red staining) over total cells (cyan DAPI nucleus stain-
ing) per organoid cultured for 6 days and exposed for the last 3 days of culture to thrombin (10 or 50 mU·mL1) or vehicle. Data are means ± SEM
with n = 5 different individuals from which tissues were harvested. Individual sign shape represents data generated from the culture of the same
patient tissue. *P < 0.05 (one-way ANOVA, Bonferroni multiple comparisons test). Photomicrographs are representative pictures of Ki67 staining
in control condition (vehicle exposure) (left panel), thrombin 10 mU·mL1 incubation (middle panel) or thrombin 50 mU·mL1 (right panel) in-
cubation. Scale bar is 50 μm.
Figure 6
PAR1 and PAR4 expression in human colon organoid cultures. (A) Relative mRNA expression of PAR1 and PAR4 in 6 day organoid cultures exposed
to vehicle (control) or to thrombin (10 and 50mU·mL1). (B) Photomicrographs representative of PAR1 immunostaining (red staining) and nucleus
staining (blue staining with DAPI) in 6 day cultures of human colon organoids (two different z stack). Data in (A) are means ± SEM of n = 5 different
individuals from which tissues were harvested. *P < 0.05 (one-way ANOVA, Bonferroni multiple comparisons test). Scale bar is 50 μm in (B).
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for PARs and PAR1 in particular in inﬂammation and inmodels
of IBD (Vergnolle, 2004; Cenac et al., 2005; Vergnolle, 2005;
Vergnolle, 2009; Vergnolle, 2016).
Most importantly, the model we used is a model originat-
ing from the human colon and, replicating at its best, a hu-
man intestinal epithelial organ. This technology is based on
the isolation of fresh intestinal crypts, which are then cul-
tured in three dimensions. The intestinal stem cells present
in the isolated crypts proliferate and enter into a differentia-
tion process, recreating a complex epithelium, containing
possibly all the cell types that compose the colonic epithe-
lium (enteroendocrine cells, goblet cells, enterocytes, etc.)
(Sato et al., 2011). This model is nowadays considered as the
best model to assess the effects of pharmacological treat-
ments on human intestinal epithelium growth and regenera-
tion (Cruz-Acuna et al., 2017). Indeed, cultured organoids are
proposed for regenerative therapies as their transplantation
can contribute to tissue repair and regeneration after injury
(Fordham et al., 2013). Above all, this model offers an unpar-
alleled strategy for recapitulating important features of hu-
man epithelial tissues and for testing pharmacological
approaches.
Thrombin is massively present in the vicinity of intestinal
epithelium in patients suffering from IBD. Indeed, bleeding is
often associated with tissue injury, and bloody diarrhoea is a
common symptom in IBD patients. In addition, studies have
reported that IBD patients exhibit a threefold higher risk for
development of systemic thrombosis than the general popu-
lation. An increased number of platelet aggregates and en-
hanced thrombin generation have been measured in IBD
patients (Senchenkova et al., 2015). The concentration of
thrombin in tissues and blood from IBD patients is in the
same range of concentrations we used in the present study,
and the same concentrations of thrombin are classically used
in in vitro models of platelet activation (de Jong et al., 1989;
Morganti et al., 2010). Therefore, the effects of thrombin on
human intestinal organoid cultures we observed could well
be informative of the endogenous effects of thrombin in
pathological situations such as IBD. In addition, by using
the organoid model, we can speculate that the level of expres-
sion of thrombin receptors in intestinal epithelial cells is
closer to physiological concentrations than those in cancer
intestinal epithelial cell lines, which are known to overex-
press PARs (Darmoul et al., 2003; Gratio et al., 2009). There-
fore, thrombin’s effects on human intestinal organoid
cultures could be considered as representative of physiologi-
cal or pathophysiological effects.
The incubation of organoid cultures in the presence of
thrombin concomitantly reduced the percentage of cystic
structures and increased the percentage of releasing struc-
tures. The squamous shape of cells in cystic structures is in-
dicative of early immature structures, which have not yet
acquired the columnar cell shape characteristic of mature co-
lonic epithelium. Our data thus suggest that thrombin is able
Figure 7
Effects of PAR1 and PAR4 antagonists on thrombin-induced changes in organoid composition, metabolic activity, apoptosis and cell proliferation.
The % of (A) cystic organoids, (B) releasing organoids and (C) budding organoids, (D) ATP concentration, (E) % of apoptotic cells per organoid
and (F) % of proliferative cells per organoid in response to thrombin (50mU·mL1 for A–C and 10 or 50mU·mL1 for D–F) added on the last 3 days
of culture in the presence of PAR1 antagonist F16357 (10 μM), PAR4 antagonist ML354 (140 nM) or vehicle, in human organoid cultures for
6 days. Data are means ± SEM of n = 5 different individuals from which tissues were harvested. (F) The ratio of proliferative cells to total cells
per organoid was calculated by use of Ki67 as a marker. *P < 0.05 (one-way ANOVA, Bonferroni multiple comparisons test).
M Sébert et al.
3664 British Journal of Pharmacology (2018) 175 3656–3668
to push organoid cultures towards a more mature phenotype.
Although not signiﬁcant, there was a trend towards an in-
creased proportion of budding structures after thrombin ex-
posure, in agreement with a pro-maturation effect of
thrombin. The low number of budding structures at 6 days
of culture might explain this lack of signiﬁcance for throm-
bin’s effects. These morphological evidences of a pro-
maturation effect of thrombin should be completed by mea-
suring differentiation markers. So far, we have investigated
the mRNA expression of the two mucus proteins MUC2 and
MUC5, but no effect of thrombin on their transcription could
be detected in organoid cultures (not shown). In the future,
more markers of all differentiated intestinal epithelial cells
should be followed. Interestingly, concomitant to the pro-
maturation effect, increased apoptosis was observed in
organoid cultures in response to thrombin exposure. This
was evidenced both by an increased staining for caspase-3 ac-
tivity and by an increased number of releasing organoids:
that is, structures full of apoptotic cells that are expelled from
the organoid. Although thrombin could favour the acquisi-
tion of a more mature intestinal epithelium phenotype, over-
all thrombin did not favour organoid growth, as the size of
cystic, columnar and releasing organoids was not modiﬁed
by thrombin exposure. On the contrary, thrombin reduced
the diameter of budding organoid structures. These structures
are considered as the most mature organoid structures. In-
deed, they present undifferentiated budding zones that corre-
spond to the crypts and more differentiated zones at the top
of those neo-formed crypts. The fact that thrombin exposure
reduced the diameter of budding structures but not of cysts or
columnar structures could suggest that thrombin inhibits the
proliferation of a speciﬁc population of progenitors present
in the developing buds. Indeed, we observed that thrombin
exposure reduced the number of proliferative cells. Interest-
ingly, at the lowest dose of thrombin used (10 mU·mL1,
the same dose that lowered the diameter of budding struc-
tures), the anti-proliferative effect of thrombin was depen-
dent on PAR4 activation. This could suggest that PAR4
activation slows organoid growth by inhibiting proliferation.
However, at a higher dose of thrombin (50 mU·mL1), which
had no effect on budding structure diameters, proliferation
was still inhibited, but this time by a mechanism involving
PAR1 activation and not PAR4 activation. This suggests that
a compensatory mechanism might maintain the size of bud-
ding organoids in the presence of this high dose of thrombin,
despite the anti-proliferative effects induced by PAR1 activa-
tion. In a previous study, we observed that PAR1-activating
peptides increase the size of murine organoids in part by
pushing differentiation processes (Nasri et al., 2016). This
could constitute the compensatory mechanism maintaining
the size of budding organoids exposed to high doses of
thrombin. Taken together, these data provide evidence that
thrombin has an anti-proliferative effect that involves both
PAR1 and PAR4 but differentially depending on the dose of
thrombin.
The same differential involvement of PAR1 and PAR4 was
observed for the effects of thrombin on metabolic activity
measured in organoid cultures. At low doses of thrombin,
PAR4 activation seemed to be involved, while at higher doses
of thrombin, PAR1 activation seemed to be responsible for
thrombin’s effects. It is well known that not the same
concentrations of thrombin are required to activate PAR1
and PAR4 on platelets (Kahn et al., 1998; Ramachandran
and Hollenberg, 2008). However, in contrast to our ﬁndings,
higher concentrations of thrombin are necessary to activate
PAR4 because of the lack of a hirudin-like thrombin binding
sequence on PAR4, while lower concentrations of thrombin
are sufﬁcient to activate PAR1, which possesses this binding
sequence (Xu et al., 1998). This apparent contradiction could
be explained by the forms of thrombin that are present in the
culture. While we added α-thrombin resuspended from ly-
ophilized powder to the organoid cultures, this form of
thrombin might not remain stable in organoid cultures, and
depending on the presence of epithelial proteases, α-
thrombin could be degraded to a certain extent to β-thrombin
and/or γ-thrombin. α-Thrombin preferably binds and cleaves
PAR1, but γ-thrombin is a much less potent agonist for PAR1
and more potent for PAR4 activation (Nystedt et al., 1994; Xu
et al., 1998). Thus, depending on the concentration of throm-
bin we add and also depending on the presence of thrombin-
cleaving proteases in our culture conditions, different forms
of thrombin at different concentrations could be present
and activate differentially PAR1 and PAR4. Indeed, in
previous studies, we demonstrated that human intestinal ep-
ithelium is a major source of proteases (Motta et al., 2011;
Motta et al., 2012; Rolland-Fourcade et al., 2017), and these
proteases, if released by organoid cultures, could cleave
thrombin. Another potential explanation could be the occur-
rence of crosstalks with other members of the PAR family. For
instance, PAR3 has been shown to act as a co-factor for PAR4
activation (Nakanishi-Matsui et al., 2000). Depending on the
expression of PAR3 together or not with PAR4 at the cell sur-
face or intestinal epithelial cells, PAR1 or PAR4 activation
might be favoured. Although PAR2 is not considered as a
thrombin receptor, recent work from the Hollenberg’s labora-
tory has demonstrated that thrombin can signal through
PAR2 (Mihara et al., 2016). We have previously shown that
activated PAR2 strongly reduced the proliferation of imma-
ture cells, although without inducing apoptosis or decreasing
stem cell capacities in mouse cultured organoids (Nasri et al.,
2016). Thus, PAR2 could be another player, activated at high
concentrations of thrombin (Mihara et al., 2016), interfering
with proliferation and metabolic activity. Further experi-
ments with selective peptidic agonists for the different PARs
would bring important pharmacological information on the
effects of each PARs. However, even the use of peptidic
agonists is a limiting factor as tethered ligand peptides do
not reproduce all signalling pathways triggered by PAR-
activating proteases (Ramachandran and Hollenberg, 2008).
Interestingly, both the PAR1 or PAR4 antagonist alone (in
the absence of thrombin) decreased metabolic activity by
one-third in organoid cultures (Figure 7D, time 0). One can
speculate that some proteases are present in intestinal epithe-
lial cells and could constitutively activate PAR1 and PAR4 in
steady states, lowering metabolic activity. Trypsin-3, a prote-
ase known to activate PAR1 and PAR4 (Knecht et al., 2007),
has recently been shown to be present in intestinal epithelial
cells (Rolland-Fourcade et al., 2017); this protease could be re-
sponsible for this effect.
It is important to note, however, that the cell assay that
was used in the present study to measure ATP levels is also re-
ported as an indicator of cell viability. In order to fully discuss
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the effects of thrombin on metabolic activity, other parame-
ters such as glycolysis, oxygen consumption or NADH activ-
ity should be measured.
The most striking effect of thrombin on human colon
organoid cultures was on the induction of apoptosis. Apopto-
sis is a physiological process in intestinal epithelium, where
highly differentiated cells at the top of the crypt undergo ap-
optosis in order to be renewed. However, excess of apoptosis
could be harmful to the mucosa, leading to an increased per-
meability and an increased presence of immature cells
(Blander, 2016). It has been shown that IBD is associated with
increased epithelial cell apoptosis and increased permeability,
the aberrant epithelial cell death being responsible at least in
part, for the delayed mucosal healing (Blander, 2016). Con-
sidering the high amounts of thrombin present in tissues
from IBD patients, and the pro-apoptotic effects we observed
for thrombin in human intestinal organoid cultures, it is
plausible to think that in IBD patients, the presence of throm-
bin in the vicinity of the epithelium participates to the in-
creased apoptosis. Indeed, here by counting only apoptotic
cells present within the epithelium lining of organoids, our
results point to direct pro-apoptic effect of thrombin on func-
tional epithelial cells and not only an increased anoikis. This
clearly suggests a detrimental effect for thrombin on func-
tional epithelium. Further, we demonstrated that both PAR1
and PAR4 activations are involved in the mechanism of
thrombin-induced apoptosis in intestinal epithelial cells. In
previous studies, we have demonstrated that PAR1 activation
provoked an increased permeability due to aberrant apopto-
sis. This was demonstrated both in vitro in epithelial cancer
cell line cultures and in vivo in a mouse model (Chin et al.,
2003). The results from the present study deﬁnitively point
to the possible same mechanism in non-transformed com-
plex human epithelium and add to the mechanism the possi-
ble involvement of PAR4.
Conclusions
The present study demonstrated the multiple effects of
thrombin in human intestinal epithelium, identifying PAR1
and PAR4 as important receptors mediating these effects.
While the pharmacological approach used here suggests that
the regulation of PAR1 and PAR4 activation by thrombin
could be subtle in human intestinal epithelial cells, depend-
ing on the concentration of surrounding thrombin, all our
data point to a detrimental effect of thrombin and its recep-
tors on epithelial growth and potential healing. These ﬁnd-
ings seem particularly relevant in the context of IBD, where
thrombin is largely present in the vicinity of epithelial cells,
and suggest that thrombin inhibition, PAR1 and PAR4 block-
ade could constitute a possible therapeutic intervention in
IBD to favour epithelial regrowth and barrier function. How-
ever, it is important to note that our study was performed in
healthy tissues, and different responses to thrombin could
be expected in tissues from IBD patients. Furthermore, by
favouring differentiation and maturation, thrombin through
the activation of PAR1 and PAR4 could also exert positive ef-
fects on epithelial repair. Further studies are necessary to in-
vestigate the effects of thrombin and PAR activation in
organoid cultures from IBD patients, discriminating between
Crohn’s disease and ulcerative colitis.
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Figure S1 Schedule of experiments. Kinetic scheme of
organoid cultures, from crypt isolation (day 0), to the addi-
tion of thrombin (10 or 50 mU.mL1) or vehicle, in the pres-
ence or not of PAR1-, PAR4- antagonists or their vehicle (from
day 3 to day 6). All analyses were performed at day 6.
Figure S2 Effects of PAR1 and PAR4 antagonists on organoid
characteristics. A – Organoid diameter (μm) of cystic, colum-
nar, releasing and budding organoids at 6-days of culture
and after 3 days of exposure to PAR1 or PAR4 antagonist
alone. B – Repartition of the different types of structures, at
6-days of culture and after 3 days of exposure to PAR1 or
PAR4 antagonist alone. Data are means ±SEM with n=5 indi-
viduals from which tissues were harvested. One-way ANOVA
was performed and F did not achieve P < 0.05.
Figure S3 Effects of PAR1 and PAR4 antagonists on the ef-
fects of Thrombin on organoid diameter. Organoid diameter
(μm) of cystic, columnar, releasing and budding organoids
at 6-days of culture and after 3 days of exposure to Thrombin
10 mU.ml-1 (A), or Thrombin 50 mU.ml-1 (B), and in the
presence of vehicle, PAR1 or PAR4 antagonist. Data are means
±SEM with n = 5 individuals from which tissues were har-
vested. One-way ANOVA was performed and F did not
achieve P < 0.05.
Table S1 Characteristics and outcomes of control patients
(NS: not-speciﬁed; NSAIDS: non-steroidal anti-inﬂammatory
drugs).
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